home All News open_in_new Full Article

Chinese biotech firm secures Pfizer deal despite trade tensions

Chinese drug maker 3SBio has licensed its new cancer drug to US pharmaceutical giant Pfizer in the largest deal ever for China’s biotech industry, underscoring the strong commercial Sino-US ties despite geopolitical headwinds. Based in Shenyang, capital of northeastern Liaoning province, 3SBio will receive a US$1.25 billion upfront payment for licensing its cancer drug SSGJ-707 exclusively to Pfizer, which will manufacture and commercialise the drug outside mainland China, the companies...


today 2 w. ago attach_file Economics

attach_file Politics
attach_file Events
attach_file Events
attach_file Events
attach_file Politics
attach_file Events
attach_file Events
attach_file Events
attach_file Events
attach_file Politics
attach_file Politics
attach_file Events
attach_file Events
attach_file Events
attach_file Events
attach_file Events
attach_file Politics
attach_file Events
attach_file Politics
attach_file Politics


ID: 1950376416
Add Watch Country

arrow_drop_down